One-Shot gene therapy could simplify cancer treatment

NCT ID NCT07574346

Recruiting now Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new injection called IASO207 for people with relapsed or refractory B-cell blood cancers. Unlike current CAR-T therapies that require removing and engineering cells in a lab, IASO207 is designed to create cancer-fighting T cells directly inside the body. The study will enroll 18 adults to check safety and see if the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IASO207 injection (a gene therapy that turns the body's own T cells into cancer-killing cells)
What this could lead to: If it works, this could lead to a simpler, one-shot treatment for certain blood cancers that avoids the complex process of removing and modifying cells outside the body.
What could go wrong: This is a very early, small trial (18 people) focused on safety, so it is far from proven. The treatment may cause serious side effects like cytokine release syndrome or may not shrink tumors at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma neoplasm primary mediastinal large B-cell lymphoma Recurrence Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANCIES

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.